The glycosaminoglycan hyaluronan is important in many tissue repair processes. We have investigated the synthesis of hyaluronan in a panel of cell lines of fibroblastic and epithelial origin in response to platelet-derived growth factor (PDGF)-BB and other growth factors.
INTRODUCTION
Hyaluronan is a glycosaminoglycan consisting of repeating disaccharide units of Dglucuronic acid and N-acetyl-D-glucosamine. It is found in particular in soft connective tissues and is the major component in synovial joint fluid, vitreous body and skin, both in dermis and epidermis, contributing both to the structural and functional integrity [1, 2] .
Hyaluronan is synthesized by three hyaluronan synthesizing enzymes (HAS1, 2 and 3) located at the plasma membrane, and the newly synthesized molecule is extruded into the extracellular space while the synthesis is in progress [3] [4] [5] . Among the three HAS isoforms, the HAS2 isoform is required for embryonic development since mice deficient in the HAS2 gene die at embryonic day E 9.5; in contrast, mice deficient in HAS1 and HAS3 genes are viable [6] .
Hyaluronan accumulation is a prominent feature of rapidly remodeling tissues. For example, during embryonic development, hyaluronan production facilitates the migration of differentiating cells and stimulates their transformation to a mesenchymal phenotype [6] .
Furthermore, hyaluronan is involved in the skin wound-healing process from the early inflammatory process to re-epithelization and remodeling [7] , and is involved in scarless fetal healing most likely by reducing collagen deposition [7, 8] . In addition, hyaluronan overproduction promotes tumorigenesis in several tumor types, whereas suppression of hyaluronan production decreases tumorigenicity [9, 10] . Accumulation of hyaluronan synthesis can arise from both increased synthesis and decreased degradation. Hyaluronan is degraded by the action of hyaluronidases (HYALs), including HYAL1, HYAL2 and PH-20 that have demonstrated bona fide hyaluronidase activity [11] . Hyaluronan degradation occurs locally in several tissues, for example in dermis where hyaluronidase activities have been demonstrated [12, 13] , however, the mechanisms of hyaluronan metabolism in the connective tissues under physiological and inflammatory conditions are still largely unknown.
Hyaluronan interacts with several cell surface receptors, such as CD44, RHAMM and LYVE-1, and extracellular components, such as versican and aggrecan [14, 15] ; through its complex interactions, hyaluronan affects a variety of physiological cellular events, such as cell proliferation, differentiation and migration. Because of its hygroscopic and viscoelastic Biochemical Journal Immediate Publication. Published on 27 Feb 2007 as manuscript BJ20061757 3 properties, hyaluronan also affects cellular behavior via remodeling of the macro-and microenviroments around cells [16] [17] [18] [19] .
Growth factors play central roles during both normal and pathological conditions, including embryogenesis, wound healing and tumor invasion, i.e. biological processes characterized by increased amounts of hyaluronan. Platelet-derived growth factor-BB (PDGF-BB) and transforming growth factor-ß1 (TGF-ß1), which are produced by both normal and transformed cells, are powerful stimulators of hyaluronan production by certain mesenchymal cells [16, [20] [21] [22] . PDGF-BB mediates its cellular effects through activation of a-and ß-tyrosine kinase receptors. Ligand binding causes receptor dimerization, leading to autophosphorylation of specific tyrosine residues in the intracellular parts of the receptors.
This creates docking sites for SH2 domain containing signaling molecules, whereby several signaling pathways are activated [23] . PDGF receptors can act synergistically with a v ß 3 integrin to promote tumor cell tissue infiltration [24] . However, recent studies in our laboratory on primary cultures of human dermal fibroblasts, revealed that high concentrations of exogenous hyaluronan negatively affects PDGF ß-receptor activation and cell migration in a CD44-dependent manner [25] . In normal fibroblast cultures, the intracellular signaling pathways that regulate the turnover of hyaluronan in response to external stimuli have not yet been clarified. Here, we demonstrate that the effect of PDGF-BB on hyaluronan synthesis in human dermal fibroblast cultures is due to induction of HAS2. In contrast, TGF-ß1 has no effect on hyaluronan synthesis but enhances hyaluronan degradation by stimulation of hyaluronidase activity. Moreover, we show that the Ras-Erk MAP kinase and PI3 kinase pathways are important for PDGF-BB-stimulated hyaluronan production in these cells, and that hyaluronan binding to its receptor CD44 is important for PDGF-BB-induced cell growth. 4 medium (grade II, 0.5 U/ml, Boehringer Mannheim / DMEM) at 4˚C, dermis and epidermis were separated, using a fine forceps. Fibroblasts from the dermal sheet explants were then cultured in complete medium (DMEM containing 10% fetal bovine serum (FBS, Biowest and antibiotics), and used between passages 6 to 10 for all experiments. Normal human epidermal keratinocytes were released from the epidermal sheets by incubation with 4 mg/ml trypsin and 4 mg/ml glucose in 0.02% EDTA at 37 o C for 1 h. After gentle pipetting, 10% FBS was added to stop the enzymatic activity, whereafter keratinocytes were washed and collected by centrifugation. Keratinocytes (60-70% confluence, passage three) were grown in EpiLife Uppsala, Sweden; medium contained also 10 µg/ml insulin), and fibroblasts derived from keloid-like dermal scars (generously provided by Bengt Gerdin, Akademiska hospital, Uppsala, Sweden).
Polyclonal antibodies against human HAS2 and HYAL2, as well as peptide synthesis
To raise polyclonal antibodies against HAS2 and HYAL2 we chose the peptide CGRRKKGQQYDMVLD that corresponds to amino acid residues 537-549 at the C-terminal domain of HAS2 and is conserved in both human and mouse HAS2 [26, 27] , and the peptide PGHAPGEPQLRPVG that corresponds to amino acid residues 398-411 at the C-terminal domain of human HYAL2 [28] . The peptides were synthesized using the N-(9-fluorenyl) methoxycarbonyl strategy which resulted in a carboxy-terminal amidated domain to facilitate subsequent coupling to Keyhole Limpet Hemocyanin for rabbit immunization. Furthermore, a cysteine residue was added to PGH peptide at the C-terminal domain, in order to facilitate a subsequent coupling to a SulfoLink resin (<http://www.jbc.org/cgi/content/full/278/41//cgi/redirect-inline?ad=Pierce> Pierce), and used to affinity purify the antibodies. The peptides were purified by reversed-phase high pressure liquid chromatography and rabbits were immunized (service by EUROGENETEC, Belgium).
The antisera were used directly or after purification on a HiTrap Protein G HP column (Amersham Biosciences), according to the instructions of the manufacturer. The hyaluronan content in 24 h conditioned media was quantified, essentially as described previously [9] . This assay is based on the highly specific and irreversible capture of proteins secreted into the conditioned medium affected the result, since treatment of the conditioned medium with proteases before the assay, had no effect (unpublished data).
Detection of HYAL activity in human dermal fibroblast cultures
The activity of HYALs in fibroblast conditioned media and cell-layers harvested after 6 h from unstimulated and PDGF-BB-or TGF-ß-stimulated cells was quantitatively estimated using a microtiter-based assay essentially as described by Frost and Stern [31] . In this assay biotinylated hyaluronan (substrate) is covalently coupled to Covalink-NH 96-well microtiter plates. After removal of the coupling solution and three washings with PBS supplemented with 2 M NaCl and 50 mM MgSO 4 , the plates were equilibrated with assay buffer (0.1 M formate, pH 3.7, 0.15 NaCl and 1% Triton X-100).
Conditioned medium from each sample supplemented with 1 µg/ml aprotinin was Notably, MEFs, 293 cells and Cos-1 cells synthesized only minute amounts of hyaluronan (Fig. 1) . The hyaluronan content in 24 h-conditioned media from subconfluent cultures of human foreskin fibroblasts AG 1518 and AG1523, as well as fibroblasts derived from normal dermis or dermal keloid scars, were increased 2 -4-fold, when cells were stimulated with PDGF-BB (Fig. 1) . Among the cells with an epithelial phenotype, primary human epidermal keratinocytes synthesized hyaluronan in a PDGF-BB-independent manner, consistent with the lack of PDGF receptors on these cells, whereas the synthesis of hyaluronan by the human epithelial cell line HaCat was stimulated by PDGF-BB. Notably, the mammary NMuMG cells did not synthesize any significant amounts of hyaluronan (Fig. 1) .
Thus, the hyaluronan synthesizing capacity of fibroblasts derived from various origins, differs upon PDGF-BB stimulation; the primary cultures of human dermal fibroblasts exhibited the highest hyaluronan production in response to PDGF-BB, compared to other cells tested, and were thus chosen for further studies.
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We next investigated the effects of other growth factors of importance for the biology of dermis, on hyaluronan synthesis at concentrations found to give maximum effects (data not shown). PDGF-BB stimulated hyaluronan synthesis in human dermal fibroblasts even more efficiently than 10% FBS ( Fig. 2A) . Epidermal growth factor (EGF) slightly increased the hyaluronan content in the conditioned 24 h media, whereas basic fibroblast growth factor (bFGF) and transforming growth factor-ß1 (TGF-ß1) had no effect. Addition of EGF together with PDGF-BB did not increase hyaluronan production appreciably over that synthesized in response to PDGF-BB alone, whereas addition of bFGF gave a slightly decreased effect.
Interestingly, addition of TGF-ß to PDGF-BB resulted in an about 72% decrease in the amount of hyaluronan compared to stimulation with PDGF-BB alone ( Fig. 2A) . These data support the notion that PDGF-BB has a major role in hyaluronan biosynthesis in dermis. The stimulatory effects of PDGF-BB were higher in primary subconfluent cultures compared with that of confluent cultures of human dermal fibroblasts (Fig. 2B ).
PDGF-BB and TGF-ß1 affect differentially the enzymes involved in synthesis and degradation of hyaluronan
As a first step to further elucidate which of the three HAS isoforms accounts for the increased levels of hyaluronan in the conditioned media of dermal fibroblast cultures, in response to PDGF-BB, we determined the mRNA levels of HAS genes in non-stimulated and PDGF-BB stimulated cells using real-time PCR. Furthermore, to investigate whether the hyaluronan degradative enzymes also contributed to the modulation of the levels of hyaluronan in the conditioned media, the levels of mRNAs for HYAL1 and HYAL2 were also determined. The analysis of non-stimulated and PDGF-BB-stimulated dermal fibroblasts, at 1 h, 4 h and 24 h, revealed that dermal fibroblasts expressed only traces of HAS1, HAS3 and HYAL1 transcripts.
PDGF-BB stimulation of the cells triggered an early and significant induction (after 1 h of stimulation) of mRNAs for HAS1 (10-fold), HAS3 (7-fold) and HYAL1 (4-fold) compared with the corresponding basal transcript levels (p < 0.05). Longer treatments of cell cultures with PDGF-BB, led to a decline in the expression levels of HAS1 and HAS3, whereas the HYAL1 transcript was high even after 4 h of stimulation, followed by a decline at 24 h.
Independently of the degree of stimulation, the mRNA levels of HAS1, HAS3 and HYAL1
were very low (between 0.01% -0.07%) compared to GAPDH. Importantly, dermal fibroblasts exhibited a high basal expression of HAS2 and HYAL2 mRNA levels, about 900-fold and 40-fold higher compared to HYAL1 (1 x sample) (Fig. 3) . The already high transcriptional activity of HAS2 gene in non-stimulated cells, was induced about 3-fold after 4
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h of stimulation with PDGF-BB; after longer treatment, the HAS2 gene expression still possessed transcriptional activity significantly higher compared to control levels (Fig. 3) .
Notably, the endogenous high transcriptional activity of HYAL2 did not significantly change from 1 h to 24 h in response to PDGF-BB. Comparing the mRNA levels of the HAS2 and HYAL2 isoforms with those of GAPDH, revealed that the HAS2 and HYAL2 transcript levels were about 36% and 0.6% in PDGF-BB-stimulated cells, respectively, of those of GAPDH.
Thus, it is likely that the induction of the HAS2 gene and, to a lesser extent, the HAS1 and HAS3 genes, rather than the suppression of HYAL1 and HYAL2 genes, accounts for the increased hyaluronan levels in response to PDGF-BB in dermal fibroblast cultures.
We next investigated, using immunoblotting, the expressions of HAS2, HYAL1 and HYAL2 protein in 6 h PDGF-BB-stimulated and quiescent fibroblast cultures (Fig. 4) . (Fig. 3) , an appreciable amount of HYAL1 protein was expressed. PDGF-BBstimulated cells expressed more HAS2 protein (Fig. 4A ) and synthesized more hyaluronan (Fig. 4D ) compared to unstimulated cells, whereas neither the HYAL1 nor the HYAL2 proteins changed significantly (Figs 4B and C). In addition, PDGF-BB-stimulated dermal fibroblasts exhibited similar activity of hyaluronidase(s) present in cell-layer extracts and conditioned media as the non-stimulated cells (Fig. 4E) . Thus, PDGF-BB-mediated stimulation of hyaluronan synthesis is due to upregulation of HAS2 expression.
Because treatment of dermal fibroblasts with TGF-ß suppressed the stimulatory effect of PDGF-BB on hyaluronan production ( Fig. 2A) , we investigated the effects of TGF-ß on the expression of HAS2, HYAL1 and 2 as well as on hyaluronidase activity present in cell-layer extracts and conditioned media. As shown in Fig. 5 , TGF-ß stimulation did not have any effect on HAS2 protein expression or hyaluronan amount in 24 h conditioned media, neither did it affect HYAL1 and 2 expressions. Interestingly, however, stimulation with TGF-ß increased, in a dose-dependent manner, the hyaluronidase activity about 3 -4-fold in conditioned media and about 2 -3-fold in cell layer extracts (Fig. 5E ). This data suggests that whereas TGF-ß does not affect the amount of HYAL1 and 2, it is a powerful stimulator of hyaluronidase activity in dermal human fibroblasts.

PDGF-BB-induced stimulation of hyaluronan synthesis requires active Erk1/2 and PI3K signaling pathways
In order to explore which signaling pathways are important for stimulation of hyaluronan biosynthesis in response to PDGF-BB, we used specific inhibitors of downstream signaling molecules at non-cytotoxic concentrations, as determined by the exclusion of trypan blue (data not shown). The PDGF-BB-induced 2.5-fold increase in the hyaluronan synthesis was completely prevented when the dermal fibroblasts were cultured in the presence of the MEK1/2 inhibitor U0126 that inhibits MEK, an activator of the MAP kinase Erk1/2, or in the presence of the PI3-kinase inhibitor LY294002 (Fig. 6A) . Notably, addition of the specific Src inhibitor SU6656 and p38 inhibitor SB203580, only slightly suppressed hyaluronan production (less than 20% inhibition), indicating that these signaling pathways does not have a major role in PDGF-BB-induced hyaluronan synthesis. Thus, the powerful stimulatory effect of PDGF-BB on hyaluronan biosynthesis is dependent on activation of PI3-kinase and Erk1/2 signaling pathways.
Further studies on the more downstream signaling molecules involved in PDGF-BBmediated hyaluronan synthesis revealed an important role of NFkB. This was demonstrated by using the SN50 peptide inhibitor which is cell-membrane permeable and contains the nuclear localization sequence of NFkB and thereby inhibits the translocation of its active complex into the nucleus. PDGF-BB stimulation of hyaluronan synthesis was decreased about 80% by the SN50 peptide. In contrast, the control SN50M peptide, which has mutations in the nuclear localization sequence of NFkB and thus does not prevent translocation of the NFkB active complex into the nucleus, did not significantly inhibit the hyaluronan produced by PDGF-BB stimulation. These observations support the notion that NFkB has a central role in the activation of hyaluronan synthesis.
Also at the transcriptional level, PDGF-BB-induced HAS2 gene expression was completely prevented if the fibroblasts were cultured in the presence of the MEK inhibitor U0126, or in the presence of the PI3-kinase inhibitor LY294002; the effects of the inhibitors on PDGF-BB-induction of HAS1, HAS3 and HYAL2 were less apparent (Fig. 7) . Furthermore, the levels of mRNAs for HYAL1 were also suppressed when these inhibitors were added to the cultures. These studies indicate an involvement of the Erk MAP kinase and PI3-kinase signaling pathways in HAS2 and HYAL1 transcriptional activities. A four hours stimulation of the cells with 10% FBS led to increases in HAS1, HAS2 and HAS3 transcripts; the increase in HAS2 transcriptional activity was similar to that detected after PDGF-BB stimulation.
Biochemical Journal Immediate Publication. Published on 27 Feb 2007 as manuscript BJ20061757
13
However, in addition, 10% FBS caused powerful inductions of HYAL1 and HYAL2 transcripts (Fig. 7) .
Inhibition of hyaluronan binding to CD44 inhibits PDGF-BB-mediated proliferation of human dermal fibroblasts
In order to investigate whether hyaluronan is of importance for the PDGF-BB-stimulated growth stimulation of dermal fibroblasts, we subjected the cells to a [ 
DISCUSSION
In the present study, we show that among various epithelial and fibroblast cells from different origins, the adult human dermal fibroblasts synthesize the highest amounts of hyaluronan. We used primary cultures of dermal fibroblasts for a thorough analysis of the effects of PDGF-BB and TGF-ß1 on the mRNA and protein levels of HAS and HYAL isoforms. PDGF-BB potently stimulated hyaluronan synthesis (Figures 1, 2) , HAS2 gene transcriptional activity (Figures 3 and 7) , and HAS2 protein induction (Fig. 4A) .
Importantly, we found that inhibition of hyaluronan binding to its receptor CD44 prevents PDGF-BB-induced [ 14 that in human dermal fibroblast cultures TGF-ß suppresses the PDGF-BB-induced hyaluronan levels ( Fig. 2A) . Most likely, the stimulatory effect of TGF-ß1 on hyaluronidase activity in dermal fibroblasts (Fig. 5E ) contributes to the lowering of the hyaluronan levels.
Interestingly, the increase in hyaluronidase activity occurred without an increase in the amount of HYAL protein. It is possible that TGF-ß induces proteolytic activation of HYAL proteins or induces the synthesis of an activation co-factor. Furthermore, TGF-ß1 stimulation of normal human mesothelial cell cultures led to suppression of HAS2 gene expression but induction of HAS1 transcript [33] . Thus, the differential effects of TGF-ß1 on hyaluronan production and degradation is cell-type specific and involves regulation of both hyaluronan synthesizing and degrading enzymes. These differences may have functional implications since hyaluronan fragments have different effects on cells compared to high molecular weight hyaluronan, and e.g. stimulates angiogenesis in a CD44-and chemokine CXCL1-dependent manner [39] .
Following activation of the PDGF ß-receptor by PDGF-BB, several signaling pathways are activated. Two of the best defined pathways, supporting cell survival and proliferation, are the Erk MAP kinase and PI3 kinase pathways (Fig. 9) . Activation of Erk MAP kinase leads to activation of the 90 kDa ribosomal S6 kinases (RSKs), that are responsible for the phosphorylation of several substrates, such as the transcription factor cAMP response element binding protein (CREB) and the transcriptional inhibitor IkB, that upon phosphorylation is targeted for ubiquitination and degradation leading to activation of NFkB and its translocation to the nucleus and binding to specific promoter elements [40] . The PI3 kinase pathway is also important in the PDGF-mediated anti-apoptotic signaling through Akt and the IkB kinase (IKK) leading to active NFkB complex [41] . As shown in Figures 6 and 7, inhibition of either of these pathways using specific inhibitors results in inhibition of both the HAS2 transcriptional activity and hyaluronan synthesis, to a similar level as for the non-stimulated cells. Notably, the proximal promoter region of HAS2 gene has putative binding sites for the CREB and NFkB transcription factors [42] (Fig. 9 ) which are downstream of the Erk MAP kinase and PI3K signaling pathways. Our finding that inhibition of either of the Erk MAP kinase or PI3-kinase pathways is sufficient to inhibit PDGF-BBinduced hyaluronan synthesis, suggests that these pathways are necessary for induction of hyaluronan synthesis in dermal fibroblasts. More recent studies on the HAS2 promoter have also identified a functional STAT-responsive element [43] ; STAT isoforms are also effector molecules downstream of the PDGF ß-receptor.
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The composition of the extracellular matrix strongly influences the phenotypes of cells [44] , and thus has important pathobiological implications. Hyaluronan and hyaluronan-CD44
complexes have been shown to be involved in the progression of inflammation and cancer [45, 46] . Thus, given the many important functions of hyaluronan and its tight regulation in response to growth factors and cytokines released in rapidly remodeling tissues, further studies on the molecular mechanisms that regulate each HAS and HYAL gene expression in response to external stimuli are needed. 
